NAPOLI-3: An open-label, randomized, phase III study of first-line liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin versus nab-paclitaxel + gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma.

Zev A. Wainberg,Tanios Bekaii-Saab,Richard A. Hubner,Teresa Macarulla,Andrew Scott Paulson,Eric Van Cutsem,Fiona Maxwell,Yan Moore,Haofei Tiffany Wang,Bin Zhang,Eileen M. O’Reilly

NAPOLI-3: An open-label, randomized, phase III study of first-line liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin versus nab-paclitaxel + gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma.

2020

Zev A. Wainberg
Tanios Bekaii-Saab
Richard A. Hubner
Teresa Macarulla
Andrew Scott Paulson
Eric Van Cutsem
Fiona Maxwell
Yan Moore
Haofei Tiffany Wang
Bin Zhang
Eileen M. O’Reilly

TPS4661Background: Liposomal irinotecan administered with 5-fluorouracil/leucovorin (5-FU/LV) is approved in the USA for metastatic pancreatic ductal adenocarcinoma (mPDAC) following progression wi...

Keywords:

Fluorouracil
Oncology
Liposomal Irinotecan
in patient
Gemcitabine
Pathology
first line
Internal medicine
Oxaliplatin
open label
pancreatic ductal adenocarcinoma
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations